ZOETIS INC (1ZTS.MI) Stock Price, Forecast & Analysis
BIT:1ZTS • US98978V1035
1ZTS.MI Key Statistics, Chart & Performance
The current stock price of 1ZTS.MI is 106.64 EUR. In the past month the price decreased by -27.3%.
1ZTS.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1ZTS.MI.
1ZTS.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1ZTS.MI. 1ZTS.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
1ZTS.MI Financial Highlights
Over the last trailing twelve months 1ZTS.MI reported a non-GAAP Earnings per Share(EPS) of 5.34. The EPS increased by 10.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.21% | ||
| ROA | 17.49% | ||
| ROE | 49.11% | ||
| Debt/Equity | 1.31 |
1ZTS.MI Forecast & Estimates
24 analysts have analysed 1ZTS.MI and the average price target is 133.48 EUR. This implies a price increase of 25.16% is expected in the next year compared to the current price of 106.64.
For the next year, analysts expect an EPS growth of 8.19% and a revenue growth 2.07% for 1ZTS.MI
1ZTS.MI Ownership
1ZTS.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.41 | 192.208B | ||
| SNW | SANOFI | 9.41 | 192.16B | ||
| 1SAN | SANOFI | 9.24 | 188.634B | ||
| MRK | MERCK KGAA | 14.91 | 55.717B | ||
| UNC | UCB SA | 27.56 | 55.124B | ||
| UCB | UCB SA | 26.85 | 53.704B | ||
| 1MRK | MERCK KGAA | 14.92 | 53.065B | ||
| 1BAYN | BAYER AG-REG | 9.38 | 45.039B | ||
| BAYN | BAYER AG-REG | 8.94 | 42.912B | ||
| IPN | IPSEN | 13.83 | 13.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1ZTS.MI
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY US
Employees: 13800
Phone: 13026587581
ZOETIS INC / 1ZTS.MI FAQ
What does ZOETIS INC do?
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Can you provide the latest stock price for ZOETIS INC?
The current stock price of 1ZTS.MI is 106.64 EUR. The price increased by 3.67% in the last trading session.
Does 1ZTS stock pay dividends?
ZOETIS INC (1ZTS.MI) has a dividend yield of 1.64%. The yearly dividend amount is currently 1.47.
How is the ChartMill rating for ZOETIS INC?
1ZTS.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about ZOETIS INC (1ZTS.MI) stock?
24 analysts have analysed 1ZTS.MI and the average price target is 133.48 EUR. This implies a price increase of 25.16% is expected in the next year compared to the current price of 106.64.
What is ZOETIS INC worth?
ZOETIS INC (1ZTS.MI) has a market capitalization of 47.00B EUR. This makes 1ZTS.MI a Large Cap stock.